FMP

FMP

Enter

FGEN - FibroGen, Inc.

photo-url-https://financialmodelingprep.com/image-stock/FGEN.png

FibroGen, Inc.

FGEN

NASDAQ

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

0.354 USD

0.0113 (3.19%)

About

ceo

Mr. Thane Wettig

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopath...

CIK

0000921299

ISIN

US31572Q8087

CUSIP

31572Q808

Address

409 Illinois Street

Phone

415 978 1200

Country

US

Employee

486

IPO Date

Nov 14, 2014

FGEN Financial Summary

CIK

0000921299

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

31572Q808

ISIN

US31572Q8087

Country

US

Price

0.35

Beta

0.7

Volume Avg.

1.73M

Market Cap

35.58M

Shares

-

52-Week

0.301-2.93

DCF

15.77

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.22

P/B

-

Website

https://www.fibrogen.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest FGEN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep